Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Diseases × Epirubicin × Clear all

Phase

Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Stomach Neoplasms 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 HER2-negative Breast Cancer 1 Carcinoma, Hepatocellular 1 Breast Diseases 1

Interventions

Tamoxifen 1 Letrozole 1 Lapatinib 1 Goserelin 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡